<?xml version='1.0' encoding='utf-8'?>
<document id="23620485"><sentence text="Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria." /><sentence text="A P-glycoprotein (P-gp) IC₅₀ working group was established with 23 participating pharmaceutical and contract research laboratories and one academic institution to assess interlaboratory variability in P-gp IC₅₀ determinations" /><sentence text=" Each laboratory followed its in-house protocol to determine in vitro IC₅₀ values for 16 inhibitors using four different test systems: human colon adenocarcinoma cells (Caco-2; eleven laboratories), Madin-Darby canine kidney cells transfected with MDR1 cDNA (MDCKII-MDR1; six laboratories), and Lilly Laboratories Cells--Porcine Kidney Nr" /><sentence text=" 1 cells transfected with MDR1 cDNA (LLC-PK1-MDR1; four laboratories), and membrane vesicles containing human P-glycoprotein (P-gp; five laboratories)" /><sentence text=" For cell models, various equations to calculate remaining transport activity (e" /><sentence text="g" /><sentence text=", efflux ratio, unidirectional flux, net-secretory-flux) were also evaluated" /><sentence text=" The difference in IC₅₀ values for each of the inhibitors across all test systems and equations ranged from a minimum of 20- and 24-fold between lowest and highest IC₅₀ values for sertraline and isradipine, to a maximum of 407- and 796-fold for telmisartan and verapamil, respectively"><entity charOffset="180-190" id="DDI-PubMed.23620485.s8.e0" text="sertraline" /><entity charOffset="195-205" id="DDI-PubMed.23620485.s8.e1" text="isradipine" /><entity charOffset="245-256" id="DDI-PubMed.23620485.s8.e2" text="telmisartan" /><entity charOffset="261-270" id="DDI-PubMed.23620485.s8.e3" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e0" e2="DDI-PubMed.23620485.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e0" e2="DDI-PubMed.23620485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e0" e2="DDI-PubMed.23620485.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e0" e2="DDI-PubMed.23620485.s8.e3" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e1" e2="DDI-PubMed.23620485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e1" e2="DDI-PubMed.23620485.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e1" e2="DDI-PubMed.23620485.s8.e3" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e2" e2="DDI-PubMed.23620485.s8.e2" /><pair ddi="false" e1="DDI-PubMed.23620485.s8.e2" e2="DDI-PubMed.23620485.s8.e3" /></sentence><sentence text=" For telmisartan and verapamil, variability was greatly influenced by data from one laboratory in each case"><entity charOffset="5-16" id="DDI-PubMed.23620485.s9.e0" text="telmisartan" /><entity charOffset="21-30" id="DDI-PubMed.23620485.s9.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.23620485.s9.e0" e2="DDI-PubMed.23620485.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23620485.s9.e0" e2="DDI-PubMed.23620485.s9.e1" /></sentence><sentence text=" Excluding these two data sets brings the range in IC₅₀ values for telmisartan and verapamil down to 69- and 159-fold"><entity charOffset="67-78" id="DDI-PubMed.23620485.s10.e0" text="telmisartan" /><entity charOffset="83-92" id="DDI-PubMed.23620485.s10.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.23620485.s10.e0" e2="DDI-PubMed.23620485.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23620485.s10.e0" e2="DDI-PubMed.23620485.s10.e1" /></sentence><sentence text=" The efflux ratio-based equation generally resulted in severalfold lower IC₅₀ values compared with unidirectional or net-secretory-flux equations" /><sentence text=" Statistical analysis indicated that variability in IC₅₀ values was mainly due to interlaboratory variability, rather than an implicit systematic difference between test systems" /><sentence text=" Potential reasons for variability are discussed and the simplest, most robust experimental design for P-gp IC₅₀ determination proposed" /><sentence text=" The impact of these findings on drug-drug interaction risk assessment is discussed in the companion article (Ellens et al" /><sentence text=", 2013) and recommendations are provided" /><sentence text="" /></document>